Aprea Therapeutics (NASDAQ:APRE – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01), FiscalAI reports.
Aprea Therapeutics Stock Performance
Shares of APRE stock traded down $0.01 during mid-day trading on Wednesday, hitting $0.51. The company’s stock had a trading volume of 19,648 shares, compared to its average volume of 828,723. Aprea Therapeutics has a 52 week low of $0.41 and a 52 week high of $1.49. The company has a market cap of $6.41 million, a PE ratio of -0.47 and a beta of 1.74. The company’s fifty day simple moving average is $0.69 and its 200-day simple moving average is $0.75.
Wall Street Analysts Forecast Growth
APRE has been the topic of several recent analyst reports. LADENBURG THALM/SH SH assumed coverage on shares of Aprea Therapeutics in a research note on Wednesday, October 14th. They issued a “buy” rating and a $2.00 target price on the stock. Wedbush dropped their price objective on Aprea Therapeutics to $3.00 and set an “outperform” rating for the company in a report on Thursday, August 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Thursday, October 15th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $2.80.
Check Out Our Latest Report on Aprea Therapeutics
About Aprea Therapeutics
Aprea Therapeutics, Inc (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Its research is centered on small-molecule treatments intended to address molecular abnormalities that contribute to tumor growth and resistance to treatment.
The company’s lead historical program was eprenetapopt, also known as APR-246, an investigational therapy designed to reactivate mutant p53, a tumor-suppressor protein frequently altered in cancer.
See Also
- Five stocks we like better than Aprea Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
